Full Press Release Details
DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal
Registration Document
DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical
company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the Company ), today announced the filing, for the year ended December 31, 2023, of its Annual Report on
Form 10-K with the U.S. Securities and Exchange Commission ( SEC ) and its Universal Registration Document ( URD ) with the French market authority, Autorit des March s
These documents can be accessed on the Investors section of the Company s website at www.dbv-technologies.com. In addition, the URD is available on the AMF s website at www.amf-france.org and the Form
10-K is available on the SEC s website at www.sec.gov.
Printed copies of both documents are
available, free of charge, at the Company s headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.
About DBV Technologies
DBV Technologies is a clinical-stage
biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin , to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions
of people live with food allergies including young children. Through epicutaneous immunotherapy (EPIT ), the Viaskin platform is designed to introduce microgram amounts of a biologically
active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual s underlying allergy by
re-educating the immune system to become desensitized to allergen by leveraging the skin s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The
Company s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Montrouge, France, with North American operations in Basking Ridge, NJ.
The Company s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company s ADSs (each representing one-half of one ordinary share) are traded on
the Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly
Twitter) and LinkedIn.
Viaskin and EPIT are trademarks of DBV Technologies.